A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patients

Trial Profile

A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patients

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Registrational
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 19 May 2017 Status changed from recruiting to discontinued.
    • 14 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top